BOUNDLESS BIO, INC.
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Boundless Bio's stock with a target price of $17.5, indicating potential growth.
Financial Health
Boundless Bio, Inc. has a solid financial position with good cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BOLD
Thrill & Excitement Fund
Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.
Published: June 17, 2025
Explore BasketHumble & Hungry
Get exclusive access to ambitious challenger companies positioned to outperform their larger competitors. Our professional analysts have carefully selected these nimble innovators for their potential to deliver explosive growth by disrupting established industry giants.
Published: June 17, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Milestone Catalysts
Clinical readouts, regulatory decisions and licensing deals can move the stock; however, outcomes are uncertain and can go either way.
R&D-Driven Value
Progress in research and development typically drives valuation for firms this size, but R&D timelines are long and results are not guaranteed.
Partnership Potential
Collaborations or strategic partnerships can provide funding and validation, though reliance on deals also introduces execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
